

| Catalog No. | MS856019 |
|---|---|
| Description |
_x005F_x000D_
_x005F_x000D_
_x005F_x000D_
_x005F_x000D_
_x005F_x000D_
_x005F_x000D_
InVivo Plus Anti-Mouse IL17A Antibody (BZN035) [BZN035] (MS856019) is a mouse monoclonal antibody detecting Interleukin-17A in FCM, Neutralization. Suitable for Mouse. _x005F_x000D_
_x005F_x000D_
_x005F_x000D_
_x005F_x000D_ Highlights _x005F_x000D_
_x005F_x000D_
|
| Species reactivity | Mouse |
| Applications | FCM, Neutralization |
| Host species | Mouse |
| Isotype | IgG2a |
| Clone ID | BZN035 |
| Clonality | Monoclonal |
| Target | Interleukin-17A, IL-17, IL-17A, Cytotoxic T-lymphocyte-associated antigen 8, CTLA-8, IL17A, CTLA8, IL17 |
| Endotoxin level | <1 EU/mg |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q62386 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). _x005F_x000D_ _x005F_x000D_1. Liang, SC. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 7791-9. PMID: 18025225 _x005F_x000D_
_x005F_x000D_
2. Ishigame, H. et al. (2009) Immunity 30, 108-19. PMID: 19144317 _x005F_x000D_
_x005F_x000D_
3. Lee, JS. et al. (2015) Immunity 43, 727-38. PMID: 26431948 _x005F_x000D_
_x005F_x000D_
4. Park, H. et al. (2005) Nature immunology 6, 1133-41. PMID: 16200068 _x005F_x000D_
_x005F_x000D_
5. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 _x005F_x000D_
_x005F_x000D_
6. Chen, K. et al. (2016) Cell host & microbe 20, 596-605. PMID: 27923703 _x005F_x000D_ |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for InVivo Plus Anti-Mouse IL17A Antibody (BZN035)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский